Are you a small or medium-sized enterprise (SME)? If so the Medicines and Healthcare Products Regulatory Agency (MHRA) fees legislation currently has provision for some payment waivers for SMEs.
What is the criteria for a small or medium company?
The criteria that needs to be met in the UK in order to be defined as a SME, is as follows:
What payment easements are available for small companies?
25% of the application fee for a new active substance at the time of the application with the remaining 75% payable within 30 days of the Marketing Authorisation (MA) being determined.
50% of the application fee for a new active substance at the time of the application with the remaining 50% payable within 30 days of the MA being determined.
Applications for Manufacturer’s or Wholesale Dealer’s licences
50% at time of application with 50% payable 12 months after that time.
In respect to inspection fees in connection with applications for a MA, traditional herbal registration, manufacturer’s licence or wholesale dealer’s licence, the fee payable is 50% within 14 days following receipt of written notice requiring those fees, with 50% payable 12 months after that date.
See detailed legislation on fees here: The Medicines (Products for Human Use) (Fees) Regulations 2016.
What payment waivers are available for SMEs?
- Fees payable in connection with a meeting mentioned in any of regulations 4 to 10, as set out in the Human Medicines (Amendments etc.) (EU Exit) Regulations 2020.
- 100% of initial application fee where the licensing authority grants an orphan marketing authorisation.
- 100% of application for variation of orphan marketing authorisation made within first 12 months of the date of grant.
This does not apply to an application to authorise use of the medicinal product in a new therapeutic area which does not meet the orphan criteria listed in regulation 50G(2) of the Human Medicines Regulations.
How do I apply for SME status?
Fusion Pharma can support you in your application for SME status in the UK.
While the information in this article is considered to be true and correct at the date of publication, changes in guidance and/or experience may impact on the accuracy of the information. Please refer to the relevant guidance for the latest information.